検索結果

. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediately (medical device approval numbe...

Animal Science | Business Activities | About Senju | SENJU Pharmaceutical

s-Enhancing Enterprise with a Consummate Pet-related Product Line Pets are our precious companions. They have the right to enjoy the same comforts we do. Through the development of animal pharmaceutic...

お知らせ | 千寿製薬株式会社

eMED”（PDF） January 17, 2025 Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF） November 26, 2024 Launch and Distribution of “MIE...

. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediately (medical device approval numbe...

. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RET-700, effect...